logo
Plus   Neg
Share
Email
Comment

SuperGroup 13-week Group Sales Rise 14% - Quick Facts

SuperGroup Plc (SGP.L) on Thursday said sales in the 13 weeks ended April 29 increased over 14 percent with growth in both retail and wholesale businesses.

Group sales climbed to 75.2 million pounds from 65.9 million pounds. Retail sales grew to 39.4 million pounds from 31.6 million pounds and like-for-like sales were flat. Online performance was strong but the challenging retail environment witnessed a slow-down in sales from stand-alone stores and concessions.

Wholesale Sales grew to 35.8 million pounds from 34.3 million pounds. The underlying growth rate was around 9 percent before adjusting for the year end translation of currency.

According to the company, the slow-down in reported growth rate of the Wholesale business was impacted by the annualisation of the SuperGroup Europe acquisition and the continued expansion of the UK Retail business. In addition, growth was adversely impacted at the end of the quarter by delays to franchise stock shipments.

Julian Dunkerton, CEO, said, ''Although the fourth quarter has been a disappointing end to a challenging year, the brand remains strong and this, together with the Group's investments in key senior personnel and system infrastructure, provides a solid platform for the coming financial year."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amid a government shutdown, the Senate voted Monday to move forward on a short-term spending bill to re-open the government. The Senate voted 81 to 18 in favor of limiting debate on the bill, which would fund the government through February 8th. Opera, a web browser for Windows, macOS, and Linux operating systems, has added cryptocurrency mining protection to its mobile browsers. It is part of the browser's ad blocker function. In its desktop-based versions, Opera had introduced cryptocurrency miner protection in early January. French drug giant Sanofi SA Monday announced an agreement to buy US-based hemophilia drugmaker Bioverativ Inc. (BIVV) for around $11.6 billion. The deal expands Sanofi's presence in specialty care and strengthens leadership in rare diseases. Sanofi shares were losing around 4 percent in the early morning trading in Paris.
comments powered by Disqus
Follow RTT